DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/fxjjrp/noninsulin_diabet) has announced the addition of the "Non-Insulin Diabetes. Management Products, Players, Markets, and Forecasts" report to their offering.
The diabetes market is changing. The convergence of environmental factors, lifestyle factors and increased patient longevity are driving double-digit growth projections for the incidence of non-insulin dependent (Type 2) diabetes globally. Type 2 diabetes accounts for about 90% of all diagnosed cases of diabetes and is increasingly being diagnosed in children and adolescents.
There are eight drug classes, analyzed in this report, with proven efficacy for aiding in glycemic control in this patient population. Because of the size and business potential of this market, pipeline activity is high. In addition to derivative products and products that combine approved APIs in a single dosage form, drugs based on newer chemistries and mechanisms that include amylin analogs and GLP-1 drugs have been introduced. Globally, revenues of drugs for managing Type 2 diabetes will grow by 14% between 2011 and 2016. Safety issues associated with post-launch-reported events will continue to be a major concern for market participants.
Highlights:
- Analyzes and evaluates non-insulin or insulin analog drug products and development-stage candidates for glycemic control
- Provides assessments of diabetes managemnet markets for non-insulin drugsl and examines key market and commercialization factors
- Evaluates the impact of economic, technology, and regulatory factors on diabetes management markets
- Provides market data and forecasts to 2016
- Profiles market sector participants, their product development activities and business strategies
Topics Covered:
Executive Summary
Diabetes Management Market Dynamics
The Economics of Diabetes
Therapeutic Options and Patient Outcomes
Evolving Healthcare Initiatives
Demand Drivers
Competitive Landscape
Risk Factors
Non-Insulin Diabetes Management - Product Development Factors
Formulation and Administration
Oral Form Factors
Injectable Formulations
Dosing Frequency
Injectable Device Strategies
Clinical Trial Factors
Combination Therapeutics
Non-Insulin Drug Therapeutics - Classes, Mechanisms and Prescribing Factors
Alpha-glucosidase Inhibitors
Amylin Analogs
Di-peptidyl peptidase IV
Glitazones (Thiazolidinediones)
Glucagon-Like Peptide-1 (GLP-1)
Metformin
Meglitinides
Sulfonylureas
Non-Insulin Drug Therapeutics - Commercial Product Assessments
Branded Drugs
Non-Insulin Diabetes Management - Market Segment Analysis & Forecasts
Analysis and Forecasts by Drug Class
Analysis and Forecasts by Region
Market Factors
Regulatory Factors
North America
European Union
Japan
Demographic Factors
Safety and Reporting
Patient Compliance Factors
Sector Participant Company Profiles
For more information, including full table of contents, please visit http://www.researchandmarkets.com/research/fxjjrp/noninsulin_diabet